☆ 4.7 Article

Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination

BLOOD (2022)

Related references

Note: Only part of the references are listed.

Review Microbiology

Characteristics of SARS-CoV-2 and COVID-19

Ben Hu et al.

Summary: This review summarizes the research progress on SARS-CoV-2 and COVID-19, including virology characteristics, pathogenesis, and recent advances in treatment methods. Furthermore, it discusses in detail the potential wildlife hosts and zoonotic origin of this emerging virus.

NATURE REVIEWS MICROBIOLOGY (2021)

Add to Collection

Article Hematology

Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia

Yair Herishanu et al.

Summary: Patients with chronic lymphocytic leukemia have a significantly impaired antibody response to the BNT162b2 mRNA COVID-19 vaccine, which is influenced by disease activity and treatment.

BLOOD (2021)

Add to Collection

Article Oncology

COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia

Lindsey E. Roeker et al.

LEUKEMIA (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

David S. Khoury et al.

Summary: The level of neutralizing antibodies is closely related to immune protection against COVID-19, playing a crucial role in protecting against detected infection and severe infection. Studies have shown that neutralizing titers will decline over time after vaccination, leading to decreased protection against SARS-CoV-2 infection.

NATURE MEDICINE (2021)

Add to Collection

Article Hematology

COVID-19 in patients with CLL: improved survival outcomes and update on management strategies

Lindsey E. Roeker et al.

BLOOD (2021)

Add to Collection

Article Oncology

Seroconversion rates following COVID-19 vaccination among patients with cancer

Astha Thakkar et al.

Summary: Most cancer patients show high seroconversion rates after receiving COVID-19 vaccines, but those with hematologic malignancies, especially after highly immunosuppressive therapies, exhibit lower conversion rates. Patients on immune checkpoint inhibitor therapy or hormonal therapy display high conversion rates.

CANCER CELL (2021)

Add to Collection

Letter Oncology

Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies

Lee M. Greenberger et al.

CANCER CELL (2021)

Add to Collection

Editorial Material Medicine, General & Internal

Confronting the Delta Variant of SARS-CoV-2, Summer 2021

Carlos del Rio et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

Add to Collection

Article Biochemistry & Molecular Biology

CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer

Erin M. Bange et al.

Summary: In patients with cancer and COVID-19, those with hematologic cancer show impaired immune responses compared to solid cancer patients. CD8 T cells play a crucial role in survival, even in the presence of limited humoral responses. The presence of SARS-CoV-2-specific T cell responses in hematologic cancer patients suggests a potential therapeutic target.

NATURE MEDICINE (2021)

Add to Collection

Letter Medicine, General & Internal

Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients

Nassim Kamar et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Letter Medicine, General & Internal

Heterologous ChAdOx1 nCoV-19 and mRNA-1273 Vaccination

Johan Normark et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Letter Medicine, General & Internal

SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3

Ann R. Falsey et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel

Yinon M. Bar-On et al.

Summary: After receiving a third dose of the BNT162b2 mRNA vaccine, Israeli residents aged 60 and above who had previously received two doses of the vaccine saw significantly lower rates of confirmed Covid-19 infection and severe illness compared to those who did not receive a booster shot, indicating the effectiveness of the booster dose in reducing infection and severe illness.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Covid-19 Breakthrough Infections in Vaccinated Health Care Workers

Moriah Bergwerk et al.

Summary: Among fully vaccinated health care workers, breakthrough infections with SARS-CoV-2 were correlated with neutralizing antibody titers during the peri-infection period. Most breakthrough infections were mild or asymptomatic, although persistent symptoms did occur.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Oncology

Weak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic malignancies

Florent Malard et al.

Summary: This study evaluated the safety and immunogenicity of the BNT162b2 vaccine in patients with hematological malignancies. It found that only around half of the patients may achieve effective immune protection against COVID-19 after receiving two doses of the vaccine. Factors such as being male, receiving B-cell targeting treatment, and having low CD19(+) B-cell levels were associated with a decreased probability of achieving a protective level of anti-S IgG after the second dose.

BLOOD CANCER JOURNAL (2021)

Add to Collection

Article Oncology

Antibody responses after first and second Covid-19 vaccination in patients with chronic lymphocytic leukaemia

H. Parry et al.

Summary: CLL patients have lower antibody responses after both first and second Covid-19 vaccine doses compared to healthy donors. Patients currently treated with BTK inhibitors or with IgA deficiency are more likely to fail to generate an antibody response after the second vaccine. This study supports the need for optimizing vaccination strategies in CLL patients, potentially including the use of booster vaccines.

BLOOD CANCER JOURNAL (2021)

Add to Collection

Article Medicine, General & Internal

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

Chaolin Huang et al.

LANCET (2020)

Add to Collection

Article Hematology

Outcomes of COVID-19 in patients with CLL: a multicenter international experience

Anthony R. Mato et al.

BLOOD (2020)

Add to Collection

Article Microbiology

A Replication-Competent Vesicular Stomatitis Virus for Studies of SARS-CoV-2 Spike-Mediated Cell Entry and Its Inhibition

M. Eugenia Dieterle et al.

CELL HOST & MICROBE (2020)

Add to Collection

Article Oncology

COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus

Lydia Scarfo et al.

LEUKEMIA (2020)

Add to Collection

Letter Oncology

Anti-SARS-CoV-2 antibody response in patients with chronic lymphocytic leukemia

Lindsey E. Roeker et al.

LEUKEMIA (2020)

Add to Collection

Article Hematology

iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL

Michael Hallek et al.

BLOOD (2018)

Add to Collection

Article Oncology

Immunoglobulin G subclass deficiency and infection risk in 150 patients with chronic lymphocytic leukemia

Jane A. Freeman et al.

LEUKEMIA & LYMPHOMA (2013)

Add to Collection

Article Immunology

Antibody response to 7-valent conjugated pneumococcal vaccine in patients with chronic lymphocytic leukaemia

Marjatta Sinisalo et al.

VACCINE (2007)

Add to Collection

Review Oncology

Immunosuppressive agents in solid organ transplantation: Mechanisms of action and therapeutic efficacy

AL Taylor et al.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2005)

Add to Collection

Article Medicine, General & Internal

Genomic aberrations and survival in chronic lymphocytic leukemia.

H Döhner et al.

NEW ENGLAND JOURNAL OF MEDICINE (2000)

Add to Collection

© Peeref 2019-2024. All rights reserved.